6. パーキンソン病 Parkinson disease Clinical trials / Disease details
臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00590122 (ClinicalTrials.gov) | October 2006 | 28/12/2007 | Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study | COMPARISON OF ORALLY DISSOLVING LEVODOPA (PARCOPA®) TO CONVENTIONAL ORAL LEVODOPA: A SINGLE DOSE, DOUBLE-BLIND, PLACEBO CONTROLLED, CROSS-OVER TRIAL | Parkinson's Disease | Drug: Parcopa;Drug: carbidopa-levodopa | Baylor College of Medicine | UCB Pharma | Completed | 31 Years | 80 Years | Both | 20 | Phase 4 | United States |
2 | NCT00139880 (ClinicalTrials.gov) | June 2005 | 29/8/2005 | A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease | A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease | Parkinson's Disease | Drug: Parcopa | UCB Pharma | NULL | Completed | 40 Years | N/A | Both | Phase 3 | United States | |
3 | NCT00139867 (ClinicalTrials.gov) | January 2004 | 29/8/2005 | A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease | A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease | Parkinson's Disease | Drug: PARCOPA | UCB Pharma | NULL | Completed | 18 Years | N/A | Both | Phase 3 | United States |